Market Overview

Takeover Approach Rumors to Gilead Sciences – Alibaba Jack Ma & CEO Sun

Share:

Focusing on coronavirus, negations privately taking place between GILD and Jiangsu Hengrui Medicine for Gilead Sciences 3 Patent in exchange for licensing royalty and revenue sharing generated by the patent

Jiangsu Hengrui Medicine Co. Ltd. (SHA: 600276) has expressed their intention to buy approximately over $45 billion worth of Gilead Science share @ 96 for licensing royalty and revenue sharing generated by the Remdesivir Gilead Sciences’ (NASDAQ:GILD) patent rights in China. Sources close to CEO Sun stated is an all-cash deal. Also, a source very close to Jack Ma “Alibaba” has shown interest in partnering with CEO SUN. 

Few sources close to the China Gov party and CEO Sun (SHA: 600276) has made an interesting offer over $900 billion in Acquuistions BID offer to GILD Gilead Sciences in an all-cash deal. That deal will give China the upper hand to create a better version of that drug to cure the coronavirus. 

Source has confirmed that GILD has retained multiple firms to review the BID of CEO SUN and Jack Ma Alibaba.

Jag News is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Reported on Thursday by anonymous icbc bank senior staff, citing people with knowledge of the matter.

Media Contact
Company Name: China Market streets
Contact Person: Hubei Liu
Email: Send Email
Phone: +861011183
State: Beijing
Country: China
Website: https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-remdesivir-patent-coronavirus-takeda-plant-sale-glenmark-spinoff-hire

View Comments and Join the Discussion!